Scarring is a common consequence of skin injuries, such as burns, wounds, surgeries, and infections, affecting millions of individuals globally. Approximately 100 million people develop scars from trauma or surgical procedures, with around 15% of these evolving into hypertrophic scars or keloids. There is a significant unmet clinical need for effective therapies, as current treatments, such as silicone gels and corticosteroid injections, often provide limited results. The growing focus on advanced scar management solutions, including gene therapies and novel biologics, is expected to drive the growth of the scars drug pipeline, offering hope for more effective and lasting treatments in the future.
The Scars Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into scars therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for scars. The scars report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The scars pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with scars treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to scars.
Scarring occurs naturally as part of the skin's healing process after injuries, such as burns, wounds, surgery, or infections. The body produces collagen to repair damaged tissue, however, sometimes this process results in abnormal scarring, such as hypertrophic scars or keloids. The scars drug pipeline focuses on developing treatments that can regulate collagen production, minimize scarring, and improve skin appearance.
Hypertrophic scars and keloids are treated with therapies like silicone gel sheets, corticosteroid injections, laser therapy, and cryotherapy. Emerging treatments include biologics, gene therapies, and advanced wound dressings that target the underlying mechanisms of scarring for better outcomes. These innovations aim to reduce recurrence and improve aesthetic results for patients.
The global incidence of scars from skin injuries, including surgery and trauma, affects approximately 100 million people, with 15% progressing to hypertrophic scars or keloids. Keloid formation is most prevalent in individuals of African or Asian descent, with higher visit rates for treatment among these groups. Epidemiological studies indicate a prevalence of 3.5% in African dermatologic patients and a 0.15% annual incidence in Taiwan.
This section of the report covers the analysis of scars drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total scars clinical trials.
The drug molecule categories covered under the scars pipeline analysis include small molecules, monoclonal antibodies, gene therapies, and peptide-based therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for scars.
The EMR scars drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in scars clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for scars. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of scars drug candidates.
The study, sponsored by Johns Hopkins University, aims to evaluate the efficacy of Elucirem (Gadopiclenol) in myocardial scar assessment during cardiac MRI. This Phase 4 study will assess the optimal dose for scar detection and compare Elucirem's performance to standard treatments. The study is expected to be completed by March 2026, with an estimated 10 participants enrolled.
The Phase 3 study, sponsored by Kringle Pharma, Inc., aims to evaluate the efficacy and safety of KP-100LI, an intracordal formulation containing recombinant human dHGF, for improving voice function in patients with vocal fold scars. The study is expected to be completed by November 2025 and will involve approximately 62 participants.
Claris Biotherapeutics, Inc. is sponsoring a Phase 1 study to assess the safety and efficacy of CSB-001 Ophthalmic Solution 0.1% in individuals with recent corneal scars. The trial, involving 20 participants, began on February 5, 2024, and is expected to conclude by February 28, 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Scars Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for scars. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within scars pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share